NASDAQHealth CareMedical DevicesSnapshot 2026-07-23
Reading RXST? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This is a turnaround investment with a focus on improving fundamentals. The current thesis state indicates that RXST has not yet shown significant recovery, but it is under watch due to potential sector support.
The market currently prices RXST as cheap compared to its peers, with a notable expectations gap. This suggests that investors may be cautious but see some potential for improvement given the sector backdrop.
Fundamentals are likely to remain under pressure in the near term, as RXST has reported weak financial performance and is behind on key management priorities. The company is also facing elevated risk with a significant probability of missing future earnings expectations.
The future of RXST hinges on its ability to meet revenue and margin targets while managing operating expenses. Additionally, performance of sector bellwethers like ABT, SYK, and MDT will be critical in determining RXST's trajectory.
Over the next 1 to 3 years, RXST's outlook will depend on its operational improvements and external sector influences. Not investment advice.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The company expects revenue of $120 to $135 million for 2026. However, sales fell 20% in Q2, which challenges this revenue outlook. The Alcon deal could still enhance long-term growth potential.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: If revenue meets or exceeds expectations, it shows recovery and supports growth.
Confirms:Q2 2026 revenue reported at $34 million or higher.
Disproves:Q2 2026 revenue reported below $32 million.
Why it matters: Working with Alcon on light-adjustable lenses could help make more money.
Confirms:There was a successful milestone in the Alcon partnership.
Disproves:No news or delays in the Alcon deal may mean problems ahead.
Why it matters: Gross margin helps us see how RxSight manages costs and makes money. This is important as revenue falls.
Confirms:Gross margin was below 70%. This shows it is hard to keep making money.
Disproves:Gross margin was above 72%. This suggests better cost control than we expected.
Why it matters: Operating costs affect profits. High costs can slow financial recovery.
Confirms:Operating expenses were over $160 million. This shows poor cost control.
Disproves:Operating costs were below $150 million. This shows better cost management.
Why it matters: Maintaining gross margin above 70% is key for profitability. It shows RxSight's ability to control costs.
Confirms:Gross margin was over 72%. This shows strong cost management.
Disproves:Gross margin was under 70%. This shows possible cost issues.
Why it matters: New leadership may bring fresh strategies that impact growth and market positioning.
Confirms one read:Look for announcements about new plans or changes from CEO Aziz Mottiwala.
Confirms the other:No new plans announced in the next quarter.
